IMAX

Analyst Note: IMAX Corporation (IMAX)

Date: 2026-06-13 Event Date: 2026-06-13

1. Structural Readiness

State: Actionable

• Conservative Entry: $41.77
• Breakout Level: $41.77 (implied by conservative entry)
• Current Price: $44.33
• Extension: +6.1% vs. conservative entry. The stock is trading above the breakout level, indicating immediate momentum.
• ATR Context:
• ATR at Breakout: 3.8% (Productive).
• Current ATR: 3.5% (Productive).
• *Analysis:* The volatility contraction from 3.8% to 3.5% suggests a stabilization of price action post-breakout, which is consistent with a healthy continuation phase rather than a chaotic spike. The volatility remains within the "productive" range, supporting a structural quality rating.

2. Thesis Layer

Classification: Tactical / Setup-Led Thesis Status: No named secular thesis is active for IMAX as of this date. This is a tactical trade driven by the confluence of a confirmed price structure and strong near-term business fundamentals. The conviction is derived from the setup quality (confirmed breakout with productive volatility) and the immediate business evidence (record box office, strong guidance, and system growth) rather than a long-term macro narrative. The trade is judged on the execution of the setup and the validity of the Q1 2026 earnings data.

3. Business Analysis

Company Overview: IMAX Corporation operates as a global entertainment technology firm specializing in delivering advanced cinematic experiences. The business model relies on a network of proprietary theater systems, digital projection, and content services. Revenue is generated through system sales, leasing agreements, revenue-sharing models with exhibitors, and digital post-production services (DMR).

Key Business Metrics (as of Q1 2026 / FY 2025):

• Network Scale: As of March 31, 2026, the company operates 1,865 IMAX Systems across 91 countries. This includes 1,798 commercial multiplexes, 10 commercial destinations, and 57 institutional locations.
• Market Penetration: The company estimates a worldwide commercial multiplex addressable market of 4,466 locations. With 1,796 systems operating as of Dec 31, 2025, penetration stands at approximately 40%, indicating significant runway for international expansion.
• Box Office Performance:
• Q1 2026: Global box office in the current quarter-to-date exceeded $100 million, up over 10% year-over-year.
• Local Language Growth: Local language films generated $62 million in box office in Q1 2026, representing 24% of global box office.
• Film Performance: "Project Hail Mary" earned over $90 million in IMAX, more than double initial projections. Tickets for select 70mm screenings sold out 9 months in advance.
• 2025 Full Year: Global box office reached a record $1.28 billion, a 13% increase over the 2019 record.
• System Installations & Backlog:
• 2025 Growth: The network grew by 3.2% in 2025, driven by 98 new installations.
• Backlog: As of Dec 31, 2025, the backlog stood at 434 IMAX Systems.
• 2026 Activity: Year-to-date (as of April 30, 2026), the company signed agreements for over 40 new and upgraded systems across 10 countries, including a record 10-system deal with HOYTS in Australia/New Zealand.
• Financial Guidance (Management Expectations):
• Management remains confident in 2026 guidance, projecting a record $1.4 billion in global box office.
• System Installations: Guidance targets 160 to 175 system installations worldwide for 2026.
• Margins: Management expects adjusted EBITDA margins in the mid-40s percent for 2026, with a forecast of >50% for the coming year.
• Market Share: Trailing twelve-month domestic box office market share was 5.4%, and global market share was 3.8%.

4. Archetype and Conviction

Archetype: Growth Leader Rationale: IMAX fits the "Growth Leader" archetype due to its ability to expand its installed base (3.2% growth in 2025, 40+ new deals in 2026 YTD) while simultaneously driving margin expansion (mid-40s EBITDA margins, targeting >50%). The business is not merely recovering; it is scaling into a new record-breaking period ($1.4B box office guidance).

Conviction Stack:

• Thesis Strength: Moderate (Tactical). The lack of a named secular thesis means the trade relies on the immediate execution of the business plan rather than a macro tailwind.
• Evidence Quality: High. The evidence base is robust, citing specific earnings transcripts (E1-E8) and SEC filings (E9-E18) with strong correlation scores (0.65–0.70). The data points to a company executing on its guidance.
• Structural Quality: High. The ATR at breakout (3.8%) and current ATR (3.5%) are in the "productive" range, indicating healthy volatility without excessive risk of a severe loser profile. The setup is confirmed, not forming.
• Rerating Potential: Moderate to High. The combination of record box office, expanding international footprint (40% penetration), and margin expansion (targeting >50%) provides a fundamental basis for multiple expansion if the market re-rates the company's growth sustainability.

Valuation Context: Forward consensus EPS is $1.70 for FY1 and $1.95 for FY2. The current price of $44.33 implies a forward P/E of approximately 26x for FY1 and 22.7x for FY2. Given the record growth trajectory and margin inflection, this valuation appears reasonable for a growth leader in a recovering entertainment sector, though the tactical nature of the setup suggests the primary driver is technical confirmation of the fundamental story.

5. Invalidations, Strengths, and Gaps

Invalidation Triggers:

• Fundamental Deterioration: A significant miss on the $1.4 billion box office guidance or a failure to deliver the 160-175 system installations would undermine the "Growth Leader" thesis.
• Margin Compression: If EBITDA margins fall below the mid-40s range despite the system growth, the margin inflector thesis would be challenged.

Strengthening Factors:

• International Expansion: Continued success in non-North American markets (e.g., the HOYTS deal) validates the 40% penetration thesis.
• Content Diversification: The 24% contribution from local language films and the success of non-Hollywood content (e.g., "Project Hail Mary") reduces reliance on a single studio slate.
• Margin Expansion: Confirmation of the >50% margin target in the coming year would be a significant catalyst.

Evidence Gaps:

• No Disconfirming Evidence: The provided evidence block contains no disconfirming data.
• Missing Long-Term Data: While 2026 guidance is strong, there is no specific evidence provided regarding the long-term sustainability of the 40% penetration rate or the specific capital expenditure requirements to achieve the 160-175 installation target.
• Macro Sensitivity: The evidence does not explicitly quantify the sensitivity of the business to potential macroeconomic downturns affecting discretionary entertainment spending, though the "record" performance suggests resilience.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: High Key risks: Failure to meet $1.4B box office guidance; Margin compression below mid-40s EBITDA target; Macro-driven decline in theatrical attendance. Expected path: Management executes on 2026 guidance, driving box office to record levels and expanding margins, which supports the current price level and potential for further technical extension. Expected horizon: 3 to 6 months, aligned with the delivery of the 2026 guidance and system installation cycle.